Analysis on clinical distribution and resistance characteristic of Acinetobacter baumannii isolated clinically from 2008-2012

doi:10.3969/j.issn.1673-8640.2014.03.010

Abstract

Abstract:

Objective　To investigate the clinical distribution and resistance characteristic trend of Acinetobacter baumannii in Huashan Hospital isolated clinically from January 2008 to September 2012,and to provide the reference for clinical rational using of antimicrobial agents. Methods　The drug-resistance of Acinetobacter baumannii and resistance characteristic trend to common antimicrobial agents were analyzed by disk agar diffusion method. Results　In the past 5 years,the detection rate of clinical isolated Acinetobacter baumannii from sputum specimens was highest,and mainly distributed in neurosurgery department and intensive care unit. The isolation rate in neurosurgery department presented obvious increasing trend from 19.6% in 2008 to 35.3% in 2012. The resistance of clinical isolated Acinetobacter baumannii was serious,and carbapenem antimicrobial agents had the obvious increasing trend. The resistance rate of imipenem rase from 57.5% in 2008 to 71.2% in 2012,the resistance rate of meropenem rase from 56.8% in 2008 to 71.7% in 2012,and the resistance rates of other lactams,cephalosporins,aminoglycosides and fluoroquinolones were 70.0%-80.0%. Conclusions　The infection of Acinetobacter baumannii is serious in mainly neurosurgery department and intensive care unit. The clinical isolates are commonly resistant to all kinds of antimicrobial agents,and carbapenem antimicrobial agents present a obvious increasing trend. Monitoring the resistance of Acinetobacter baumannii should be strengthened for preventing resistant bacteria from spreading.

Key words: Acinetobacter baumannii, Antimicrobial agent, Resistance rate

CLC Number:

R446.5

XU Yiming，WANG Bei，JIANG Xiaofei.. Analysis on clinical distribution and resistance characteristic of Acinetobacter baumannii isolated clinically from 2008-2012[J]. , 2014, 29(3): 245-248.

References

[1] Durante-Mangoni E,Zarrilli R. Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance[J].Future Microbiol,2011,6(4):407-422.
[2] 李永丽.鲍曼不动杆菌多重耐药机制及耐药基因检测研究进展[J].检验医学,2012,27(11):963-968.
[3] 袁红萍,周文俊,高卫亚,等.重症监护病房鲍曼不动杆菌及铜绿假单胞菌的耐药性监测[J].检验医学,2014,29(1):91-92.
[4] 李继霞,公衍文.多重耐药菌医院感染状况分析[J].检验医学,2013,28(9):784-788.
[5] Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing[S]. M100-S18,CLSI,2008.
[6] Peleg AY,Seifert H,Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen[J]. Clin Microbiol Rev,2008,21(3): 538-582.
[7] Dijkshoorn L,Nemec A,Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii[J]. Nat Rev Microbiol,2007,5(12): 939-951.
[8] 王玉月,史伟峰,周军.广泛耐药鲍曼不动杆菌氨基糖苷类药物获得性耐药基因研究[J].检验医学,2013,28(11):1008-1011.
[9] 赵付菊,刘华勇,周丽芳,等.泛耐药鲍曼不动杆菌耐药性和同源性分析[J].检验医学,2013,28(3):194-198.
[10] Vila J,Martí S,Sánchez-Céspedes J. Porins,efflux pumps and multidrug resistance in Acinetobacter baumannii[J]. J Antimicrob Chemother,2007,59(6): 1210-1215.
[11] Gordon NC,Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance[J].Int J Antimicrob Agents,2010,35(3): 219-226.
[12] 汪复,朱德妹,胡付品,等.2008年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2009,9(5):321-329.
[13] 汪复,朱德妹,胡付品,等. 2009年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志,2010,10(5):325-334.
[14] 朱德妹,汪复,胡付品,等. 2010年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志,2011,11(5):321-329.
[15] 胡付品,朱德妹,汪复,等. 2011年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志,2012,12(5): 321-329.
[16] Lee K,Yong D,Jeong SH,el al.Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens[J].Yonsei Med J,2011,52(6): 879-891.